New biologic shows promise for Tough-to-Treat ulcerative colitis
NCT ID NCT06626165
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether mirikizumab, a biologic drug, can improve symptoms and gut healing in 100 people with moderate-to-severe ulcerative colitis who had a specific type of inflammation seen on biopsy. Participants received either mirikizumab or vedolizumab, and doctors tracked changes in clinical activity and endoscopic scores. The goal is to see if mirikizumab offers a better option for patients not responding to standard maintenance therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mirikizumab (a biologic drug given by infusion or injection)
What this could lead to
If successful, this could confirm that mirikizumab helps control moderate-to-severe ulcerative colitis in patients with a specific type of gut inflammation.
What could go wrong
This is a small, completed Phase 4 study (100 people) without published results yet. It compares two existing drugs, so no breakthrough is expected, and individual responses may vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Showa Inan General Hospital
Komagane, Nagano, 399-4117, Japan